WO2004013303A3 - Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease - Google Patents

Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease Download PDF

Info

Publication number
WO2004013303A3
WO2004013303A3 PCT/US2003/024332 US0324332W WO2004013303A3 WO 2004013303 A3 WO2004013303 A3 WO 2004013303A3 US 0324332 W US0324332 W US 0324332W WO 2004013303 A3 WO2004013303 A3 WO 2004013303A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cell disease
annexin proteins
modified annexin
sickle
Prior art date
Application number
PCT/US2003/024332
Other languages
French (fr)
Other versions
WO2004013303A2 (en
Inventor
Anthony Allison
Original Assignee
Surromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surromed Inc filed Critical Surromed Inc
Publication of WO2004013303A2 publication Critical patent/WO2004013303A2/en
Publication of WO2004013303A3 publication Critical patent/WO2004013303A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.
PCT/US2003/024332 2002-08-02 2003-08-01 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease WO2004013303A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40071802P 2002-08-02 2002-08-02
US60/400,718 2002-08-02

Publications (2)

Publication Number Publication Date
WO2004013303A2 WO2004013303A2 (en) 2004-02-12
WO2004013303A3 true WO2004013303A3 (en) 2004-10-07

Family

ID=31495864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024332 WO2004013303A2 (en) 2002-08-02 2003-08-01 Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Country Status (1)

Country Link
WO (1) WO2004013303A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159841A (en) * 2013-03-18 2013-06-19 江苏省原子医学研究所 Method for marking Cys-Annexin V by use of 99mTc and application of method

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1734983A4 (en) * 2004-03-11 2009-11-18 Alavita Pharmaceuticals Inc Modified annexin proteins and methods for preventing thrombosis
WO2012120130A1 (en) 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
CN103159842B (en) * 2013-03-18 2015-07-01 江苏省原子医学研究所 Cys-Annexin V kit used for 99mTc labeling and preparation method and application thereof
EP4065152A1 (en) * 2019-11-25 2022-10-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE19541284A1 (en) * 1995-11-06 1996-05-30 Kalden Joachim Robert Prof Dr Immunomodulation method
US5612460A (en) * 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US6312694B1 (en) * 1998-07-13 2001-11-06 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5612460A (en) * 1989-04-19 1997-03-18 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
DE19541284A1 (en) * 1995-11-06 1996-05-30 Kalden Joachim Robert Prof Dr Immunomodulation method
US6312694B1 (en) * 1998-07-13 2001-11-06 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159841A (en) * 2013-03-18 2013-06-19 江苏省原子医学研究所 Method for marking Cys-Annexin V by use of 99mTc and application of method

Also Published As

Publication number Publication date
WO2004013303A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
PL1615952T3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
PL374586A1 (en) Bispecific anti-erb-b antibodies and their use in tumor therapy
ATE542801T1 (en) 2,4-PYRIMIDIINDIAMINES SUITABLE FOR THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISEASES AND DISEASES OF THE IMMUNE SYSTEM
EP1578364A4 (en) Compositions and methods for the treatmentof immune related diseases
WO2004050707A3 (en) Tumor-specific recognition molecules
HK1097704A1 (en) Process for producing protein hydrolysate and protein hydrolysate
PT1572087E (en) Antibodies against cancer antigen tmeff2 and uses thereof
NO20031251D0 (en) Process for Preparing Small Soy-Based Meals with Low Fat and High Protein Content
WO2003063796A3 (en) Heterocyclic arylsulfonamidobenzylic compounds
EP1664739A4 (en) Inline processing and irradiation system
WO2005009366A3 (en) Restoring vascular function
DE60206289D1 (en) USE OF BIBN4096 IN COMBINATION WITH OTHER MIGRANTS FOR THE TREATMENT OF MIGRAINE
WO2004013303A3 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
IL166706A0 (en) Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
AU2003259246A8 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
WO2004083241A3 (en) Btc-interacting proteins and use thereof
FI961584A (en) Oligopeptides derived from C-reactive protein fragments
AU2003227861A8 (en) Protein involved in cancer
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2002018575A3 (en) Genes expressed in the cell cycle
AU2003269378A1 (en) Methods and compositions for diagnosing and treating companion animal cancer
AU2002314594A8 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP